HIGHLIGHTS
- What: The authors evaluate CDKI73`s activity in prostate cancer and demonstrate that it promotes apoptosis and inhibits signaling by AR, MYC, and BRD4. Collectively, the work demonstrates that CDKI-73 has activity in a diverse array of aggressive prostate cancer subtypes, including AR-driven and ARindependent disease. Viewed collectively, the work undertaken to date exploring CDKI73 as a clinical development candidate is very encouraging.
- Who: Razia Rahman from the Animal studies All protocols for animal experiments were approved by the Animal Ethics Committee of the University of South Australia, Adelaide, Australia (project number:, ) and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.